Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: J Bone Miner Res. 2013 Jan;28(1):46–55. doi: 10.1002/jbmr.1740

Figure 2. FGF23 modulates FGFR signaling in PBMCm.

Figure 2

2A. Effect of FGF23 (100 ng/ml) on MAPK and Aktsignaling in PBMCm. Data are shown as representative Western blots showing expression of protein for: total MAPK; phosphoMAPK (pMAPK); total Akt; phosphoAkt (pAkt). PBMC were pre-treated under conditions of serum deprivation (0.1% human serum) for either 1 hr or 2 hrs with or without an FGFR inhibitor (FGFRi, 250 nM), and then treated with or without vehicle or FGF23 (100 ng/ml) for a further 1 hr. 2B. Quantification of changes in expression of pMAPK (1 hr pre-treatment, left panel) and pAkt (2 hr pre-treatment, right panel) expression normalized to total MAPK and Akt respectively. Data were determined using ImageJ software and represent mean ± SD values for n = 3 separate donor PBMCm cultures. ** = statistically different from vehicle-treated PBMCm, p < 0.01. ## = statistically different from FGF23-treated PBMCm, p < 0.01.